$Novo-Nordisk A/S (NVO.US)$BNP Paribas Initiates Novo Nordisk at Underperform Rating, $61 Price Target. It comes from 145 and they downgrade. I think this is definitely the bottom price to enter. And they don't explain why? Perhaps they want buy because they know already some results on 7 mai? Novo Nordisk Share Valuation from Andersen, he sees Novo’s shares as undervalued at a 32% discount to its estimated fair value of DKK 640. W...
$Novo-Nordisk A/S (NVO.US)$v long since i last updated nvo. it seems weekly chart its holding on to the light blue demand zone. 70 still remains the key level as it was the breakout resistance to the entire upper huge bullrun. the possiblity of going down to as low as 45 remains. (green demand zone). LLY at least its holding on to the last thin line of defence. NVO is totally cooked. but if it ever regains 70 and weekly 200ma (79). i believe there should be a pretty strong rally. if one were to ...
$Novo-Nordisk A/S (NVO.US)$But, why don't mention the Target price for Novo-Nordisk. By why not mention the New Blockbuster for Heart failure, the only one in the World if it's come out. Why always for obesitas? >>> "Novo Nordisk’s €1 billion investment in CARDIOR PHARMACEUTICALS strongly suggests potential blockbuster territory. Especially since it involves CDR132L, a novel RNA-based therapy for heart failure, a condition tha...
1
Report
Money Thrill
OP
:
And that is a matter of life and death. Will definitely be paid back well!
$Novo-Nordisk A/S (NVO.US)$ Is this stock seen as a long term (2 years) stock? I've already DCA down several times and my average is still at 85. When will I get out of this
Money Thrill
:
Denmark has not yet imposed any import duties on America which is good news so everything will be fine. Novo also has a special new medicine >> through the acquisition of Cardiac Pharmaceuticals for 1 billion euros it has a good medicine for heart disease. Maybe a new blockbuster
Money Thrill
:
Especially for you CatMeow ... don't worry ... wait shall go up to 100 and even more ...Novo Nordisk’s €1 billion investment in Cardior Pharmaceuticals strongly suggests potential blockbuster territory. Especially since it involves CDR132L, a novel RNA-based therapy for heart failure, a condition that affects millions of people worldwide. Here are a few reasons why this could indeed be a potential blockbuster: Novel mechanism of action: CDR132L targets microRNA-132, which plays a role in pathological cardiac tissue repair. By inhibiting this, the heart may be able to recover better after damage, something that existing drugs RARELY ADDRESS !!! THAT'S GOOD Huge market potential: Heart failure is a leading cause of death worldwide, with more than 6 million patients in the US alone. There is an urgent need for novel therapies with truly impactful effects. Competitive advantage: There are currently few effective, disease-modifying therapies on the market for heart failure, especially at the genetic or RNA level. If CDR132L lives up to its promise, it could be a first-in-class blockbuster. Phase 2 clinical trials are already underway – an indication that Novo Nordisk is also buying time and getting closer to commercial launch with the acquisition. So yes, there is a good chance that CDR132L will be their next big asset outside of the diabetes/obesity segment. Conclusion... wait
$Novo-Nordisk A/S (NVO.US)$1. Liquidity position Cash and cash equivalents + Short-term investments: Novo Nordisk has approximately DKK 26.308 billion in liquid assets (DKK 15.655 + DKK 10.653 billion). This is positive, because a healthy cash position means that the company has sufficient resources to cover operational costs and repay short-term obligations. Interpretation: A strong liquidity position helps to absorb unexpected expenses or temporary setbacks. The fact...
$Novo-Nordisk A/S (NVO.US)$Good news is that he company is expanding a separate manufacturing site in the US, which does not source products from Brazil. So no taxes
2
Report
No comment yet
Sign in to post a comment
Market Insights
Best Growth Stocks Best Growth Stocks
Spot stocks with huge growth potential and solid financial standing. Spot stocks with huge growth potential and solid financial standing.
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
U.S. Crypto Concept Stocks U.S. Crypto Concept Stocks
Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data. Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data.
Novo-Nordisk A/S Stock Discussion
Novo Nordisk Share Valuation from Andersen, he sees Novo’s shares as undervalued at a 32% discount to its estimated fair value of DKK 640. W...
"Novo Nordisk’s €1 billion investment in CARDIOR PHARMACEUTICALS strongly suggests potential blockbuster territory. Especially since it involves CDR132L, a novel RNA-based therapy for heart failure, a condition tha...
Is this stock seen as a long term (2 years) stock? I've already DCA down several times and my average is still at 85. When will I get out of this
Cash and cash equivalents + Short-term investments:
Novo Nordisk has approximately DKK 26.308 billion in liquid assets (DKK 15.655 + DKK 10.653 billion). This is positive, because a healthy cash position means that the company has sufficient resources to cover operational costs and repay short-term obligations.
Interpretation:
A strong liquidity position helps to absorb unexpected expenses or temporary setbacks. The fact...
No comment yet